TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05813899

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PS23 heat-treated
Description: PS23 heat-treated, 2 caps daily use

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PS23 heat-treated
Description: PS23 heat-treated, 2 caps daily use
Study: NCT06048991

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Thermographic assessment
Description: Patients will undergo a termographic evaluation of the operated knee of ACL reconstruction and of the controlateral knee.
Study: NCT06552325

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single Session Narrative Therapy
Description: The proposed single session narrative therapy intervention has been widely implemented in walk-in therapy clinics in Ontario Province, Canada. In these clinics, 60-minute psychotherapy sessions, informed by narrative therapy, are available on a walk-in basis. The therapist collaborates with a patient to co-develop a useful and meaningful focus for the session and then engages the patient in conversation that is respectful but shifts their way of thinking about the presenting problem. The therapist highlights and documents the patient's values and skills and works with the patient to create an action plan. If the therapist identifies additional treatment needs, the patient is offered an external referral to specialty mental health services.
Study: NCT05457127

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automatic Positive Airway Pressure (APAP)
Description: If eligible, participants will be given a clinical Automatic Positive Airway Pressure (APAP) device for up to 3 months, while they are waiting for their clinical evaluation from a sleep physician. The APAP device will we will be using is the ResMed Airsense 11 Autoset. APAP is a smart positive airway pressure (PAP) device, where the pressure changes as needed to provide optimal pressure to splint the upper airway. Dr. Lee and Dr. Schmickl will oversee management of the device.~During the first month of APAP use, individuals will participate in weekly phone calls or in-person visits to ensure optimal adherence and troubleshoot any issues (improper mask fitting, discomfort, etc) that may arise.
Study: NCT04077151

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP Demonstration Project
Description: In phase 2, a culturally, developmentally, and gender-affirmative intervention to increase uptake of and adherence to PrEP among TW and TM youth will be developed by incorporates the PK data from phase 1 and data gathered from focus groups and in-depth interviews with young transgender women and transgender men. During phase 3, this intervention will be given to the experimental arm and tested versus a standard-of-care control group.
Study: NCT05667454

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine Ophthalmic 0.05%
Description: Atropine 0.05% sulphate ophthalmic solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine Ophthalmic 0.5%
Description: Atropine 0.5% sulphate ophthalmic solution
Study: NCT05894473

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor-Motor Dual Task Physical Exercises
Description: Only physical exercise and motor dual tasks will be given
Study: NCT06377111

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: C-PAN
Description: C-PAN is an essential nutrient as it is required for the synthesis of CoA, a key cofactor in the tricarboxylic acid cycle and fatty acid metabolism, as well as for the synthesis of acyl carrier protein. Pantothenate appears to be safe in humans with studies describing the administration of doses up to 10 grams per day over prolonged periods of time; hence, no upper limit for tolerability has been established. In this study, oral supplement consisting of 2000 mg daily of C-PAN will be administered to a single cohort of patients.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is an ICI, a type of immunotherapy. It is a monoclonal antibody that binds to the protein PD-1 on the surface of immune cells called T cells. Nivolumab 1 mg/kg every 3 weeks for up to 4 cycles (upon patient´s tolerability) followed by maintenance Nivolumab 3 mg/kg (or fixed dose 240 mg) every 2 weeks or Nivolumab 6 mg/kg (or fixed dose 480 mg) every 4 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is an ICI, a type of immunotherapy. It is a monoclonal antibody that binds to the protein CTLA-4 on immune cells called T cells. Ipilimumab 3 mg/kg every 3 weeks for up to 4 cycles.
Study: NCT05894473

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor-Motor Dual Task Physical Exercises
Description: Only physical exercise and motor dual tasks will be given

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor-Motor Dual Task Physical Exercises
Description: Only physical exercise and motor dual tasks will be given
Study: NCT04311450

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss (BWL) counseling
Description: This therapy is a weekly treatment which focuses on making gradual and modest lifestyle changes with goals of establishing regular patterns of eating, setting weekly goals, decreasing caloric intake, developing coping skills, and increasing physical activity.
Study: NCT06058091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RY_SW01 cell injection
Description: Administer basic treatment with an injection of RY_SW01 cell solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RY_SW01 cell injection
Description: Administer basic treatment with an injection of RY_SW01 cell solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Basic treatment
Description: Basic treatment for SSc

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basic treatment
Description: Basic treatment for SSc

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basic treatment
Description: Basic treatment for SSc
Study: NCT04179617

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5% nicotine content JUUL pod
Description: JUUL pods that contain 5% nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3% nicotine content JUUL pod
Description: JUUL pods that contain 3% nicotine
Study: NCT05699200

Intervention type: OTHER
Group type: OTHER
Intervention: Arterial Tonometry
Description: We will measure arterial stiffness using arterial tonometry.

Intervention type: OTHER
Group type: OTHER
Intervention: Arterial Tonometry
Description: We will measure arterial stiffness using arterial tonometry.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Echocardiogram
Description: We will collect limited ultrasound images of the heart.
Study: NCT05407090

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic supplementation
Description: Participants enrolled in the probiotic group will receive probiotics for 12 weeks before surgery.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Participants enrolled in the placebo group will receive a placebo instead of probiotics.
Study: NCT06187116

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapist consultation
Description: The consultation with the PT is 40-45 minutes long according to usual care and includes patient history, assessment and management according to an assessment template. If the patient is found not to be appropriate for surgery they can receive the following; 1) self-care without follow up appointment, 2) referral to PT in primary care for rehabilitation, 3) referral back to general practitioner (GP) for new tests/assessments/medication. If the patient is found to be appropriate for surgery, and wishes to undergo surgery, or if the PT in the study wants a second opinion, the patient is 4) referred for orthopaedic consultation for surgical consideration.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orthopaedic surgeon consultation
Description: The consultation with the OS is 20-30 minutes long and includes medical history, assessment and management plan, all according to usual care. It the patient is found not to be appropriate for surgery they can receive the following; 1) self-care without follow up appointment, 2) referral to PT in primary care for rehabilitation, 3) referral back to GP for new tests/assessments/medication. If the patient is found appropriate for surgery, and wishes to undergo surgery, the patient is 4) scheduled for surgery.
Study: NCT05699200

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Echocardiogram
Description: We will collect limited ultrasound images of the heart.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Carotid Ultrasounds
Description: We will perform ultrasound imaging of the carotid artery.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Carotid Ultrasounds
Description: We will perform ultrasound imaging of the carotid artery.
Study: NCT05412394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Liquid, 5mg/kg per week, for one year
Study: NCT05637723

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: schroth exercise
Description: The schroth exercise program will be given 3 days a week for 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional scoliosis exercises
Description: The traditional scoliosis exercises program will be given 3 days a week for 6 weeks.
Study: NCT05087641

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IAB System
Description: Bronchoscopic implantation of one or multiple IABs
Study: NCT06395428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: Intramuscular injection of drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine
Description: Intramuscular injection of drug
Study: NCT05724368

Intervention type: DIAGNOSTIC_TEST
Intervention: Fecal Calprotectin ELISA kit
Description: * Routine stool examination will be done in addition to certain concentration, staining and culture techniques.~* Fecal calprotectin will be evaluated using ELISA kits according to the manufacturer's instructions.

Intervention type: DIAGNOSTIC_TEST
Intervention: Fecal Calprotectin ELISA kit
Description: * Routine stool examination will be done in addition to certain concentration, staining and culture techniques.~* Fecal calprotectin will be evaluated using ELISA kits according to the manufacturer's instructions.

Intervention type: DIAGNOSTIC_TEST
Intervention: Fecal Calprotectin ELISA kit
Description: * Routine stool examination will be done in addition to certain concentration, staining and culture techniques.~* Fecal calprotectin will be evaluated using ELISA kits according to the manufacturer's instructions.
Study: NCT06306378

Intervention type: DIAGNOSTIC_TEST
Intervention: social memory levels and spindle levels
Description: Take a face recognition memory test, and a car recognition memory test as a control . Then record nighttime EEG recordings after the two tasks and performed subsequent spindle analysis.So conduct the correlation between social memory levels and the level of spindles in the EEG by using machine learning to model.

Intervention type: DIAGNOSTIC_TEST
Intervention: social memory levels and spindle levels
Description: Take a face recognition memory test, and a car recognition memory test as a control . Then record nighttime EEG recordings after the two tasks and performed subsequent spindle analysis.So conduct the correlation between social memory levels and the level of spindles in the EEG by using machine learning to model.
Study: NCT06063733

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital pursed lip breathing intervention
Description: After registration, participants will watch an educational video on the developed software, covering the definition, benefits, and techniques of pursed lip breathing. Following this, participants will engage in pursed lip breathing interventions, guided by voice and animated instructions from the software. These sessions will occur three times daily (morning, afternoon, and night) for 10 minutes each, lasting for 8 weeks.~After each session, participants can choose to post texts on a peer social forum for peer support. Fellow participants can give 'comments' or 'likes'. The principal researcher will oversee texts, peer comments, removing information containing personal data, medical recommendations, and negative comments.~Additionally, participants can earn health points by performing specific actions (e.g., watching the educational video and practicing pursed lip breathing) on the software, encouraging their participation in related activities.
Study: NCT06491732

Intervention type: DEVICE
Intervention: Electrical Impedance Myography
Description: EIM is an impedance-based technology in which an imperceptible, high-, multi-frequency (e.g., 1 kHz to 10 MHz) electrical current is applied across two electrodes; the resulting voltage signals are measured across two sense electrodes
Study: NCT06147531

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Delayed Cold-Stored Buffy Coat Platelets
Description: To prepare cold-stored platelets, blood banks will transition conventional room temperature platelets up to 4 days after collection (with agitation) to cold-storage (at 1-6 C without agitation) for a minimum of 1 day (24 hours) and a maximum of 10 days after collection (for a total shelf life of ≤ 14 days after collection). Thus, cold-stored platelets will be produced and stored the same way as room temperature platelets up until their transition to cold-storage, ensuring similar products differing only in storage conditions and expiration date (as cold-stored platelets will have an expiration date beyond the current 5 days for pathogen inactivated platelets or 7 days for bacterially cultured platelets). Pathogen reduced platelets will be used for the pilot study (Canada is transitioning in 2022-23 to pathogen-reduced platelets and one site has already transitioned).
Study: NCT05699200

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Elastography
Description: We will measure the elastic properties of the arteries using elastography.
Study: NCT06147531

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Room Temperature Buffy Coat Platelets
Description: Room temperature stored platelets are prepared from donor whole blood, which is centrifuged to collect the buffy coat layer containing platelets. Seven ABO matched buffy coats from male and/or female donors are pooled in 280 ml of platelet additive solution and split into a single dose after pathogen inactivation, resulting in a product with a final platelet count of approximately 1300 x 109. Pathogen inactivated platelets (shelf-life of 5 days, with recent Health Canada approval for an extension of the shelf-life to 7 days), will be used as Canada is transitioning in 2022-23 to pathogen-inactivated platelets and one site has already transitioned.
Study: NCT05699200

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Elastography
Description: We will measure the elastic properties of the arteries using elastography.

Intervention type: OTHER
Group type: OTHER
Intervention: Ankle-Brachial Index
Description: We will measure the ankle-brachial index to assess peripheral artery blood flow.

Intervention type: OTHER
Group type: OTHER
Intervention: Ankle-Brachial Index
Description: We will measure the ankle-brachial index to assess peripheral artery blood flow.

Intervention type: OTHER
Group type: OTHER
Intervention: Microneurography with sympathoexcitatory maneuvers
Description: We will measure sympathetic nerve activity at rest and in response to isometric handgrip, mental stress test, cold pressor test, Valsalva maneuvers.

Intervention type: OTHER
Group type: OTHER
Intervention: Microneurography with sympathoexcitatory maneuvers
Description: We will measure sympathetic nerve activity at rest and in response to isometric handgrip, mental stress test, cold pressor test, Valsalva maneuvers.
Study: NCT06170788

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sacituzumab tirumotecan
Description: IV infusion
Study: NCT06341335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cadonilimab
Description: iv, q3w
Study: NCT06170788

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study: NCT04731506

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Connections
Description: The program starts with 2 small group support sessions spaced one week apart that guides participants through developing an action plan; followed by 10 IVR calls (5-10 minutes) beginning with weekly (4), biweekly (4), and monthly (2) calls. During each IVR call parents provide information on current physical activities, and food consumption that is used to provide feedback on success in subsequent IVR calls.
Study: NCT05698706

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TOOsonix System ONE-M
Description: Selected BCC sites will be treated using high intensity focused ultrasound
Study: NCT06341335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pulocimab
Description: iv, q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: iv, q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: iv, q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: iv, q3w
Study: NCT05176587

Intervention type: OTHER
Intervention: Follow-up of patients undergoing bariatric surgery : integrated pathway
Description: Integrated pathway : multidisciplinary, pre- and post-operative, care course for patients undergoing bariatric surgery
Study: NCT05454865

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Jin Si Herbal Tea
Description: Jin Si Herbal Tea 1 pack PO bid for 2 treatment cycles (1 cycle = 3 weeks)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 1pack PO bid for 1 treatment cycle (1 cycle = 3 weeks) and followed by Jin Si Herbal Tea 1 pack PO bid for the 2nd treatment cycle
Study: NCT06071676

Intervention type: OTHER
Group type: OTHER
Intervention: conventional impression group
Description: Silicon impression material loaded on plastic tray and inserted inside the patient mouth

Intervention type: OTHER
Group type: OTHER
Intervention: digital impression group
Description: direct scanning was done using intraoral scanner to the female housing of the attachments on position
Study: NCT03378414

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravenous infusion
Description: Intravenous infusion of mesenchymal stem cells: 2 \* 10\^7 cells (30ml)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrathecal injection
Description: Intrathecal injection of mesenchymal stem cells: 2 \* 10\^7 cells (1ml)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord mesenchymal stem cell
Description: Treat patients with umbilical cord mesenchymal stem cell (SCLnow 19#), the dosage based on different procedure

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord mesenchymal stem cell
Description: Treat patients with umbilical cord mesenchymal stem cell (SCLnow 19#), the dosage based on different procedure
Study: NCT05298787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLS-0071
Description: RLS-0071 is administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLS-0071
Description: RLS-0071 is administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLS-0071
Description: RLS-0071 is administered as an IV infusion
Study: NCT05582473

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: LST-LC Education
Description: Testing the LST-LC intervention with cultural adaptations integrated through Stage 2 (Adaptation Design). There are 9 modules.~Session 1, we describe the principles underlying the program (safety, hygiene, dignity, comfort, and independence), discuss self-care, and introduce a vignette of caring for a person with dementia, designed to generate conversation around the caregiving role.~Other modules focus on 1) behavioral and 2) communication challenges in the context of dementia; 3) home safety, transfers, and adaptable medical equipment; 4) managing nutrition needs; 5) swallowing challenges; 6) supporting oral hygiene; 7) dealing with incontinence, including preventing and recognizing urinary tract infections; 8) medication management and 9) managing comorbidities including assessing and managing pain
Study: NCT05499858

Intervention type: OTHER
Group type: OTHER
Intervention: Spiced
Description: Vegetables provided to volunteers will be spiced.

Intervention type: OTHER
Group type: OTHER
Intervention: Plain
Description: Vegetables provided to volunteers will be plain.
Study: NCT05827731

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cesarean section
Description: According to the different outcomes of pregnancy, the patients were divided into natural delivery group and cesarean section group
Study: NCT06349772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zynrelef
Description: Zynrelef will be injected at the 12mm port site

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: Exparel will be injected at the 12mm port site
Study: NCT05298787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLS-0071
Description: RLS-0071 is administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLS-0071
Description: RLS-0071 is administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLS-0071
Description: RLS-0071 is administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLS-0071
Description: RLS-0071 is administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Placebo
Description: Placebo is administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Placebo
Description: Placebo is administered as an IV infusion
Study: NCT05168553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Revascualrization
Description: Regain pulp vascularity for mature permenant teeth

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional endodontic treatment
Description: Root canal treatment of permenant mature teeth with mechanical preparation and cleaning followed by canal obturation by inert material ( gutta percha)
Study: NCT05298787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Placebo
Description: Placebo is administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Placebo
Description: Placebo is administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Placebo
Description: Placebo is administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Placebo
Description: Placebo is administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Placebo
Description: Placebo is administered as an IV infusion